NCT03746847

PET Imaging in Patients With Suspected Cardiac Sarcoidosis

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 20 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors. The study will see how the tracer is taken up in your heart before and after treatment using an imaging scan called Positron Emission Tomography / Computed Tomography (PET/CT). Investigators are doing this research study to find out if DOTATATE can help doctors diagnose people with cardiac (heart) sarcoidosis better as well as serve as a follow-up monitoring tool for a response to therapy.

Conditions

• Cardiac Sarcoidosis

Interventions

Type	Name	Description
DRUG	Gallium-68 DOTATATE	Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.

Timeline

• Start date: 2018-12-01
• Primary completion: 2022-12-01
• Completion: 2022-12-01
• First posted: 2018-11-20
• Last updated: 2022-12-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study